Sökning: "Hodgkin’s lymphoma"
Visar resultat 16 - 20 av 48 avhandlingar innehållade orden Hodgkin’s lymphoma.
16. Transcriptional regulation of the Epstein-Barr virus nuclear antigen 1 gene in latent and lytic stages of infection
Sammanfattning : Epstein-Barr virus (EBV) is a lymphotropic herpesvirus that infects more than 90% of humans worldwide. The virus is the causative agent of infectious mononucleosis, a self-limiting lymphoproliferative disorder, and is also associated with a variety of malignancies including Burkitt's lymphoma (BL), Hodgkin's disease (HD), nasopharyngeal carcinoma (NPC), and lymphoproliferative disorders in immunocompromised individuals. LÄS MER
17. Clinical and immunopathological studies in Hodgkin's disease with special reference to prognosis
Sammanfattning : Hodgkin's disease (HD) and non-Hodgkin lymphoma (NHL) have certain features in common, but also distinct clinical and pathological differences. Thus, HD has many features of both an infectious (fever, leukocytosis, eosinophilia, night sweats, lymphadenopathy, splenomegaly) and a malignant process with few tumour cells, T-cell accumulation and sclerosis. LÄS MER
18. Living and Dying with Primary Sjögren's Syndrome Studies on Aetiology, Treatment, Lymphoma, Survival and Predictors
Sammanfattning : This work was aimed at improving our understanding of the course of primary Sjögren's syndrome (SS). The Malmö SS patient register and the 2002 American-European Consensus Criteria formed the basis of all studies. Helicobacter pylori (H. LÄS MER
19. Standardization and application of quantitative PCR methods in patients with hematological malignancies
Sammanfattning : Using modem combination chemotherapy regimens, it has been possible to increase the rate of complete remission (CR) in acute lymphoblastic (ALL) and acute myeloid leukemia (AML). The major reason for treatment failure in acute leukemia (AL) is the resistance of leukemic blasts to chemotherapeutic agents, which is accompanied by an inability of the immune system to eradicate residual leukemic cells surviving initial treatment. LÄS MER
20. Targeted CD52 therapy in lymphoid malignancies : a clinical and immunological study
Sammanfattning : There is a great need for developing new treatment alternatives in low grade non Hodgkin's lymphoma (NHL) including chronic lymphocytic leukemia (CLL). The CD52 antigen, which is expressed on almost all lymphoid malignancies, can be utilized as a target for CD52-directed monoclonal antibody therapy (alemtuzumab, Campath-1 H). LÄS MER